Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2113070 | 0.84 | MEN1 (0.32) | MEN1KMT2AATMHCAR2 | |
| SCHEMBL2113073 | 0.84 | MEN1 (0.32) | MEN1KMT2AATMHCAR2 | |
| SCHEMBL11809471 | 0.82 | TSHR (0.48) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL27812005 | 0.82 | TSHR (0.48) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL20530243 | 0.82 | HCAR2 (0.48) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL29374091 | 0.82 | HCAR2 (0.48) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL11011985 | 0.81 | L3MBTL1 (0.40) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL9495093 | 0.78 | ATM (0.59) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL973521 | 0.78 | ATM (0.59) | MEN1KMT2ANPSR1ATMHPGD | |
| SCHEMBL2273956 | 0.78 | ATM (0.59) | MEN1KMT2ANPSR1ATMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | MEN1 992/4885KMT2A 318/4885NPSR1 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.